HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Klaus Friese Selected Research

Nelfinavir (Viracept)

12/2013Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
10/2010Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
6/2010New prospects for nelfinavir in non-HIV-related diseases.
1/2010The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
1/2010Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.
2/2009Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
12/2008Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Klaus Friese Research Topics

Disease

61Breast Neoplasms (Breast Cancer)
01/2022 - 01/2002
61Neoplasms (Cancer)
10/2018 - 07/2003
29Carcinoma (Carcinomatosis)
06/2016 - 06/2004
19Ovarian Neoplasms (Ovarian Cancer)
06/2014 - 05/2005
15Neoplasm Metastasis (Metastasis)
01/2022 - 01/2005
11Endometrial Neoplasms (Endometrial Cancer)
12/2013 - 07/2007
8Carcinogenesis
01/2018 - 01/2005
8Lymphatic Metastasis
04/2014 - 01/2005
7Infections
01/2017 - 01/2009
7Adenocarcinoma
10/2013 - 01/2003
6Pre-Eclampsia (Preeclampsia)
01/2019 - 12/2005
6Ductal Carcinoma
04/2014 - 01/2005
6Spontaneous Abortion (Miscarriage)
04/2011 - 02/2008
5Trophoblastic Neoplasms (Trophoblastic Tumor)
01/2013 - 06/2004
5Carcinoma in Situ
07/2007 - 03/2005
5Noninfiltrating Intraductal Carcinoma (DCIS)
07/2007 - 01/2005
4Uterine Cervical Neoplasms (Cancer of the Cervix)
10/2018 - 01/2011
4Inflammation (Inflammations)
01/2015 - 03/2012
4Endometriosis
03/2013 - 01/2009
3Uterine Cervical Dysplasia
02/2019 - 07/2007
3Rupture
01/2019 - 04/2010
3Ovarian Epithelial Carcinoma
08/2014 - 10/2012
3Endometrioid Carcinoma
05/2010 - 05/2005
3Necrosis
01/2009 - 09/2007
3Hydatidiform Mole (Molar Pregnancy)
12/2008 - 07/2007
3Hemolysis
09/2008 - 11/2006
3Hyperplasia
01/2006 - 01/2003
3Polyps
06/2005 - 01/2003
2Chorioamnionitis
01/2019 - 01/2010
2Circulating Neoplastic Cells
06/2016 - 01/2013
2Premature Birth (Birth, Premature)
03/2015 - 04/2013
2Lobular Carcinoma
04/2014 - 05/2005

Drug/Important Bio-Agent (IBA)

19Hormones (Hormone)IBA
06/2016 - 01/2002
19ParaffinIBA
06/2016 - 01/2003
15Inhibins (Inhibin)IBA
10/2013 - 01/2005
14GlycodelinIBA
03/2014 - 03/2005
12Activins (Activin)IBA
07/2011 - 01/2005
11Estrogen ReceptorsIBA
01/2018 - 09/2003
11Proteins (Proteins, Gene)FDA Link
01/2013 - 03/2005
10Estrogen Receptor alphaIBA
01/2018 - 12/2005
9AntigensIBA
10/2018 - 05/2005
9Mucin-1 (CA 15-3 Antigen)IBA
06/2016 - 07/2007
8Pharmaceutical PreparationsIBA
12/2013 - 12/2008
8Monoclonal AntibodiesIBA
05/2010 - 01/2005
7Biomarkers (Surrogate Marker)IBA
02/2015 - 03/2008
7Tumor Biomarkers (Tumor Markers)IBA
04/2014 - 01/2005
7Nelfinavir (Viracept)FDA Link
12/2013 - 12/2008
7Messenger RNA (mRNA)IBA
10/2013 - 01/2002
7Steroid Receptors (Steroid Receptor)IBA
05/2010 - 05/2005
6Estrogens (Estrogen)FDA Link
01/2018 - 07/2007
6Progesterone Receptors (Progesterone Receptor)IBA
10/2016 - 07/2007
6AntibodiesIBA
01/2013 - 05/2005
61-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA
12/2011 - 06/2004
6Galectin 1 (LGALS1)IBA
06/2011 - 06/2004
6Estrogen Receptor betaIBA
01/2009 - 12/2005
5Cadherins (E-Cadherin)IBA
01/2022 - 05/2005
5GTP-Binding Proteins (G-Protein)IBA
01/2018 - 11/2012
5EpitopesIBA
06/2016 - 01/2007
5Thomsen-Friedenreich antigenIBA
05/2013 - 06/2005
5HIV Protease InhibitorsIBA
10/2010 - 12/2008
4PPAR gammaIBA
03/2014 - 09/2007
4Biological ProductsIBA
12/2013 - 11/2003
4Glycoproteins (Glycoprotein)IBA
07/2013 - 01/2007
4Estradiol (Delestrogen)FDA LinkGeneric
01/2013 - 07/2007
4CytokinesIBA
11/2012 - 09/2008
4CarbohydratesIBA
10/2012 - 05/2005
4Peptides (Polypeptides)IBA
10/2012 - 05/2005
4TamoxifenFDA LinkGeneric
01/2010 - 01/2002
4Neoplasm Antigens (Tumor Antigens)IBA
07/2007 - 05/2005
3Galectin 3 (LGALS3)IBA
06/2016 - 02/2011
3DNA (Deoxyribonucleic Acid)IBA
10/2014 - 10/2012
3GonadotropinsIBA
08/2014 - 01/2012
3Cathepsin DIBA
04/2014 - 05/2005
3RNA (Ribonucleic Acid)IBA
03/2013 - 10/2012
3LH Receptors (LH Receptor)IBA
01/2013 - 05/2011
3SteroidsIBA
11/2012 - 07/2007
3ProgesteroneFDA LinkGeneric
11/2012 - 07/2007
3Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
01/2012 - 07/2007
3Indicators and Reagents (Reagents)IBA
05/2011 - 11/2003
3LigandsIBA
12/2009 - 06/2005
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2009 - 06/2005
3inhibin beta A subunitIBA
05/2009 - 01/2005
3Sialyl Lewis X AntigenIBA
02/2009 - 05/2005
3progesterone receptor AIBA
01/2009 - 07/2007
3EnzymesIBA
09/2008 - 11/2006
2Interleukin-4 (Interleukin 4)IBA
06/2016 - 04/2013
2Immunoglobulin M (IgM)IBA
06/2016 - 05/2005
2GlycosyltransferasesIBA
08/2015 - 01/2015
2hydrogen sulfite (bisulfite)IBA
10/2014 - 02/2014
2Peptide Hydrolases (Proteases)FDA Link
04/2014 - 07/2007
2Protein Isoforms (Isoforms)IBA
12/2013 - 10/2012
2Formaldehyde (Formol)FDA Link
02/2013 - 07/2007

Therapy/Procedure

25Therapeutics
06/2016 - 01/2002
6Cesarean Section (Caesarean Section)
03/2015 - 01/2009
5Mastectomy (Mammectomy)
06/2014 - 07/2003
4Drug Therapy (Chemotherapy)
10/2014 - 09/2007
4Adjuvant Chemotherapy
05/2014 - 01/2007
3Mammaplasty (Breast Reconstruction)
06/2014 - 06/2006
3Lymph Node Excision (Lymph Node Dissection)
05/2010 - 09/2003
2Contraindications
01/2019 - 06/2006